Morning Brief — September 4, 2026

Market Overview

Bitcoin’s surge past $81,000, fueled by Fed Governor Waller’s dovish pivot signal, is the dominant force today — dragging crypto equities up 10–18% and lifting risk appetite broadly. Treasury yields pulling back toward 4.78% are giving rate-sensitive growth names room to breathe, with SNOW’s blowout earnings adding a second pillar to the tech rally. August jobs data drops today and is the key swing factor: a soft number validates Waller’s stance and extends the rally; a hot print reverses it fast.

Claude’s Call

UP — The Waller rate-hold signal plus Bitcoin’s breakout above $81K creates genuine dual-engine momentum that’s hard to fade on jobs day; the path of least resistance is higher unless payrolls surprise materially to the upside, and with yields already easing, the bar for a reversal is higher than usual.

Top Movers

MSTR (+17.6%) — $144.82 → $152.53 (+5.3% upside from here) Thesis: Pure Bitcoin leverage play firing on all cylinders — BTC above $81K is the only catalyst that matters here, and it’s real. MSTR holds ~200K+ BTC and acts as a 2-3x amplifier on Bitcoin moves, which is exactly what you’re seeing today. Technically, it’s at the 20-day high of $144.82 and just reclaimed the 50-day SMA ($103.42) in style. The RSI at 27.89 is surprising given the move — suggesting this bounce is from deeply oversold territory, not a frothy top. Still 26% below the 6-month high of $195.94, so there’s structural room above. Levels: Exit at Fib 38.2% retracement resistance at $152.53. Support at Fib 50% at $139.12 — lose that and the 50-day SMA at $103 becomes the next floor.

SNOW (+16.6%) — $356.47 → $420.49 (+18.0% upside) Thesis: This is the real deal — SNOW reported 35% revenue growth and the market is finally believing the AI data platform story after months of skepticism. The move is earnings-driven, not sympathy, which gives it staying power. Technically, it’s at a fresh 6-month high, having blown through prior resistance levels — the Fib 1.272 extension at $420.49 is the next logical target. The 50-day SMA at $297.55 is now deep support, meaning there’s a wide moat below. The caveat: at 118x forward P/E vs. the peer median of 15.7x, you’re paying an extreme premium — this is a growth-at-any-price situation, and any guidance softness would be punished severely. Levels: Exit at Fib 1.272 extension at $420.49. Support at $300.93 (Fib 23.6% from the 6mo range).

SMMT (+17.3%) — $17.13 → $19.40 (+13.3% upside) Thesis: Summit Therapeutics is moving on genuine Phase III data showing ivonescimab outperforming Merck’s Keytruda in lung cancer — this is binary biotech catalyst of the highest order, not sector noise. Beating Keytruda, the world’s best-selling drug, in a head-to-head trial is the kind of result that rewrites the narrative for a small biotech. Technically, it’s at a 20-day high but still 35% below the 6-month peak of $26.38 — the recovery is real but not over-extended. The 50-day SMA at $14.20 provides strong underlying support. Levels: Exit at Fib 50% resistance at $19.40, then $21.05 if momentum holds. Hard support at the 50-day SMA ($14.20) — below that, the story breaks down.

IOT (+15.9%) — $44.92 → $46.23 (+2.9% upside near-term), $51.77 (longer) Thesis: Samsara beat on revenue (30% YoY growth) and guided Q3 above consensus — this is a clean earnings beat with acceleration in transportation and geographic expansion into Mexico providing real operational color. Management sounded confident, not defensive. Technically, IOT is at a 6-month high near $41.87 and pushing into new territory — the Fib 1.272 extension at $46.23 is the immediate target. Volume ratio at 0.49 is the best on this list aside from LULU, suggesting real institutional participation, not thin float action. Of all today’s movers, this is the one with the cleanest fundamental + technical combination. Levels: Exit at Fib 1.272 at $46.23 near-term, $51.77 Fib 1.618 on a multi-week hold. Support at $38.09 (Fib 23.6%) — a healthy pullback target if the market turns.

HCM (+17.2%) — $14.11 → $17.30 (+22.6% upside) Thesis: HUTCHMED just landed a $1.3B deal with GSK — $110M upfront for ex-China rights to its KRAS-EGFR therapy — and that’s a legitimizing event for what was a deeply under-followed oncology name. Two separate brokers reiterated Buy, calling out a “deep valuation disconnect.” The 17% gap-up on news is the kind of move that can sustain because it’s de-risking a pipeline asset with a Big Pharma partner. Technically, it’s at a 20-day high of $14.28 but still 10% below the 6-month peak at $15.74, with the Fib 1.272 extension at $17.30 as the logical target. Levels: Exit at $17.30 (Fib 1.272). Support at $13.54 (Fib 38.2%) — that’s your stop zone.

COIN (+10.1%) — $192.70 → $199.12 (+3.3% near-term) Thesis: Crypto rally + operational catalysts = double tailwind. COIN is benefiting from Bitcoin’s $81K move but also adding its own fuel: filing for SEC approval on equity perpetuals and launching derivatives in Canada are regulatory progress items that matter for the long-term story. At $192.70, it’s just below the Fib 23.6% resistance at $199.12 from the 6-month range — a clean breakout there opens $216 (the 6-month high). The 50-day SMA at $163 is strong support. Levels: Exit at $199.12 (Fib 23.6% resistance), then $216.60 (6-month high). Support at $170.82 (Fib 61.8%).

BE (+8.4%) — $235.55 → $259.39 (+10.1% upside) Thesis: Bloom Energy is riding two separate tailwinds today — dovish Fed commentary (rate-sensitive clean energy names love falling yields) and genuine AI data center demand for behind-the-meter power solutions. The potential S&P 500 inclusion call from Stephens adds index-buying catalyst on top. At $235.55, it’s sitting right at the Fib 50% support level ($232.68) from the 6-month range — technically this is a bounce off support, not a chase. Still 32% below the 6-month high of $345.85, suggesting meaningful recovery room. Levels: Exit at $259.39 (Fib 38.2% resistance). Support at $232.68 (Fib 50%) and the 50-day SMA at $226.26 right below — tight stop zone.

HOOD (+16.6%) — $124.72 → $140.92 (+13.0% upside) Thesis: Robinhood’s fastest-growing business is now surpassing crypto revenue — analyst price target hikes piling on top of a structural mix-shift story is a legitimate re-rating catalyst. The AMC CEO controversy (calling out HOOD’s tokenized stock trading) is noise and may actually highlight HOOD’s product innovation edge. At $124.72, it’s at the 6-month high — breakout territory. The RSI at 24.84 is oddly low for a stock at all-time highs, which often signals the move has more fuel. Fib 1.272 extension at $140.92 is the first target. Levels: Exit at $140.92 (Fib 1.272). Support at $110.66 (Fib 23.6%) and the 50-day SMA at $102.41.

Headlines to Watch

“Bitcoin Rises Above $81,000 as Rate Hike Expectations Ease” — The Waller signal is the macro catalyst that unlocks the entire crypto complex; if jobs data confirms a soft labor market, $85K+ BTC is on the table and crypto equities have another leg up.
“Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug” — Ivonescimab outperforming Keytruda in a Phase III NSCLC trial is genuinely historic; watch for MRK’s response and whether FDA expedited review news follows — SMMT could double again if partnership talks emerge.
“HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy” — $110M upfront from GSK is a major validation signal for HCM’s pipeline; Panmure/Cavendish Buy reiterations flagging “deep valuation disconnect” are worth taking seriously given the catalyst quality.
“Samsara Q2 revenue jumps 30% as transportation, Mexico fuel growth” — IOT’s beat-and-raise is the cleanest earnings story of the week; the transportation acceleration theme also reads well for adjacent logistics tech names.
“Watch These 2 Energy Stocks — S&P 500 Addition Could Come Before Quarter’s End” — Bloom Energy (BE) and Cheniere as potential S&P 500 additions before quarter-end would trigger forced index-fund buying — this is a hard, quantifiable catalyst.
“Coinbase files for SEC approval to offer equity perpetuals” — This is a regulatory frontier move; SEC approval would be a watershed for tokenized equity markets and could be the next major re-rating event for COIN beyond the Bitcoin cycle.
“UiPath Posts Revenue Beat. The Stock Falls.” — PATH’s -14% reaction to a beat is a stark reminder that guidance disappointment crushes even solid quarters; a warning sign for other high-multiple software names reporting soon — check your exit levels.

Claude’s Top Picks

IOT (+15.9% today, +9.1% week) — $44.92 → $51.77 (+15.2% upside) Valuation: FAIR vs. peers at 44.7x forward P/E against peer median of 38x — slightly rich but justified by 30% revenue growth and GAAP profitability progress. Upside: Clean beat-and-raise with transportation acceleration and Mexico expansion providing multi-quarter runway — this is a fundamentals-driven move, not a meme. Risk: Already at 6-month highs; if the market turns on a hot jobs print today, high-multiple software names will be the first sold.

HCM (+17.2% today, +13.6% week) — $14.11 → $17.30 (+22.6% upside) Valuation: No comp data available, but $110M upfront vs. a stock that was $10 three weeks ago implies the market still hasn’t fully priced the $1.3B total deal value — there’s a meaningful valuation gap here. Upside: GSK partnership de-risks the KRAS-EGFR asset and provides non-dilutive capital; broker upgrades today with “valuation disconnect” thesis add institutional tailwind. Risk: China-based company with ex-China rights deal — geopolitical overhang on the retained China rights is a permanent discount factor that could cap upside.

SMMT (+17.3% today, +19.5% week) — $17.13 → $21.05 (+22.9% upside) Valuation: Negative P/E (pre-profit biotech) — valuation is irrelevant here; this is a pipeline event-driven story where the Keytruda comparison is the entire thesis. Upside: Beating Keytruda in a Phase III head-to-head creates a best-in-class narrative that attracts Big Pharma partnership interest — the 6-month high of $26.38 is the medium-term target. Risk: FDA regulatory review is still ongoing — any safety signal, label restriction, or timeline delay collapses this trade; biotech binary risk is real even after positive Phase III data.

BE (+8.4% today, +8.1% week) — $235.55 → $259.39 (+10.1% upside) Valuation: No comp data provided, but the AI data center power demand narrative is a structural re-rating catalyst — the stock is still 32% below its 6-month high, suggesting the market hasn’t fully priced the new demand environment. Upside: S&P 500 inclusion catalyst (Stephens call) + AI power demand + falling yields is a three-way tailwind that doesn’t require a perfect macro environment to work. Risk: Current price is right at the Fib 50% support level ($232.68) — if that breaks and rates reverse on a hot jobs print, BE could give back today’s gains quickly.

MSTR (+17.6% today, +5.4% week) — $144.82 → $152.53 (+5.3% near-term) Valuation: 2.8x forward P/E vs. peer median 15.7x — technically “CHEAP” by the comps, though this is an unconventional comp; what matters is NAV premium to BTC holdings, which compresses at current levels. Upside: Bitcoin above $81K is the only input that matters, and with Waller’s rate-hold signal and soft jobs data possible today, BTC has a clear path to $85K+ which would push MSTR toward $170. Risk: RSI at 27.89 despite a 17% day is a data anomaly worth flagging — and MSTR is famously volatile in both directions; it’s still down 26% from its 6-month high, meaning the downtrend hasn’t fully reversed.

Avoid

BULLW (+19.7%) — At a fresh 6-month high of $3.76 on vol_vs_avg of just 0.02 — that’s near-zero volume confirmation on the biggest move of the day. This is a thin-float micro-cap ($3.65 price) moving on Webull/Robinhood sector sympathy, not company-specific news. Chasing a 20% move with no volume is a trap.

ASST (+10.3%) — Up 116% in August alone on Bitcoin treasury accumulation, already at its 6-month high with the Fib 38.2% support all the way down at $19.83 — that’s a 26% drawdown risk to the nearest meaningful support. The analyst explicitly calling “sell the stock, buy Bitcoin” is the right framing; ASST is a NAV discount play that can evaporate faster than BTC itself.

RIOT (+13.4%) — RSI at 1.01 is a data anomaly that suggests extreme technical distortion, not a clean setup. Bitcoin miner with mixed analyst signals (Buy ratings vs. Zacks #4 Sell on declining earnings estimates), and its Bitcoin collateral-release thesis is speculative. The 6-month high is $28.69 — it’s already 26% below that while the sector rallies, which is relative underperformance worth respecting.

WSB Sentiment Check

LULU — WSB says: BULLISH (80% bullish, 372 mentions, 6,015 upvotes) Claude says: DISAGREE — LULU is at a fresh 6-month low of $100.82, sitting 42% below its 6-month high of $173.21, below all meaningful Fib supports, and volume is running at 1.6x average — that’s a capitulation flush, not a bottom. The 50-day SMA is at $118.41, a full 17% above current price. WSB is catching a falling knife and calling it a bargain; wait for a base to form before calling the bottom.

NVDA — WSB says: BEARISH (30% bullish, 172 mentions) Claude says: PARTIALLY AGREE — NVDA is at a 6-month high of $232.43, hugging the upper end of its range, with the nearest Fib support not until $218.83. After a massive AI-driven run, near-term profit-taking risk is real. But the structural AI capex story doesn’t reverse on one jobs print — bearish as a short-term trade makes sense, but calling a top on NVDA is the perennial widow-maker. Cautious, not short.

TSLA — WSB says: BULLISH (80% bullish, 141 mentions) Claude says: PARTIALLY AGREE — TSLA’s Cybercab launch in Austin is a real operational milestone, and the stock has held above its 50-day SMA at $358.05 well. But at $359.13, it’s sitting right at the Fib 61.8% retracement support ($354.45) — it needs to reclaim $371-376 (20-day high) to confirm a breakout. The robotaxi thesis is legitimate but the valuation still prices perfection. Tactically bullish but not chasing above $376.

MU — WSB says: MIXED (55% bullish, 140 mentions) Claude says: AGREE WITH MIXED — MU at $994 is sitting right at the Fib 23.6% support of $1,002.95 after pulling back from $1,213 — technically it’s at a potential bounce zone, but the stock has given back 18% from its high. Memory cycle dynamics are notoriously difficult to time. The 50-day SMA at $937.81 is the next real support if this level breaks. Mixed is the right call — not a clean trade either direction today.

AVGO — WSB says: BEARISH (30% bullish, 121 mentions) Claude says: AGREE — AVGO has fallen from $480 to $358, below its 50-day SMA at $383.68, and is approaching the Fib 61.8% support at $364.71. The selloff from highs reflects post-AI-hyperscaler-capex concerns, and with the stock still trading at a premium to peers, the risk-reward skews to more downside before stabilization. Until it reclaims $383 (50-day SMA), the chart is bearish.

Earnings Scorecard

SNOW — REPORTED | Stock: +16.6% | Reported: After Close Thursday The 35% revenue growth and beat on AI data platform demand is the genuine article — the reaction is fully justified and arguably the first time in 12 months the stock has deserved its premium. Not a sell-the-rip; the Fib 1.272 extension at $420.49 is the next rational target if AI cloud spending holds.

PATH — REPORTED | Stock: -14.0% | Reported: After Close Thursday This is the classic “beat on revenue, miss on forward guidance” punishment — Q2 GAAP profitability was record-setting but the market sold the forward deceleration story hard. At analyst target of ~$14.31, the stock is trading near or at that level already, suggesting most of the bad news is priced. Watch for a stabilization trade but don’t bottom-fish until guidance credibility is re-established — hold, not buy.

CIEN — REPORTED | Stock: +1.2% | Reported: After Close Thursday Record revenue, lifted guidance, and yet the stock barely moved — the earlier headline shows it was actually down 10% intraday before recovering, suggesting the initial reaction was an overreaction to “in-line guidance” fears. The +1.2% close vs. a -10% intraday is a buy-the-dip vindication. Ciena’s AI networking backlog story is intact — the mild close after a brutal intraday is actually a constructive setup.

ADYEY — REPORTED | Stock: +0.08% | Reported: H1 2026 Adyen raised its growth guidance and shares are essentially flat — the market wanted more. An 11% stock jump on acquisition-driven revenue targets suggests the underlying move already happened; the 0.08% close-to-close is a digestion pattern. Not a trade either way today — hold if you own it.